Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSH | P09668 | 1/20 | 0.46 |
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CCR5 | P51681 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | MPI | P34949 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | GRM5 | P41594 | 2/20 | 0.35 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3275602 | 0.84 | KMT2A (0.77) | KMT2AOPRK1CTSBCTSHMETAP2 | |
| SCHEMBL7171554 | 0.82 | KMT2A (0.74) | KMT2AOPRK1CTSBCTSHMETAP2 | |
| SCHEMBL28898898 | 0.80 | KMT2A (0.71) | KMT2AOPRK1CTSBCTSHMETAP2 | |
| SCHEMBL5217451 | 0.78 | KMT2A (0.49) | KMT2AOPRK1CTSBCTSHMETAP2 | |
| SCHEMBL12416583 | 0.77 | CCR1 (0.41) | KMT2AOPRK1CTSBCTSHMETAP2 | |
| SCHEMBL31556365 | 0.77 | CCR1 (0.41) | KMT2AOPRK1CTSBCTSHMETAP2 | |
| SCHEMBL3961491 | 0.77 | CCR1 (0.41) | KMT2AOPRK1MAPTRAB9ACCR1 | |
| SCHEMBL17542880 | 0.77 | KDM4E (0.38) | KMT2AOPRK1METAP2MAPTKDM4E | |
| SCHEMBL4174305 | 0.77 | KMT2A (0.56) | KMT2AOPRK1CTSBCTSHMETAP2 | |
| SCHEMBL17774714 | 0.77 | KMT2A (0.56) | KMT2AOPRK1CTSBCTSHMETAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | GLAXO GROUP LIMITED | 2010-08-12 | — | — | US | disclosed |
| US-7732600-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-2145622-A1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | Glaxo Group Limited (GB) | 2010-01-20 | — | — | EP | disclosed |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2009-12-17 | — | — | US | disclosed |
| EP-1876174-B1 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LTD (GB) | 2009-11-11 | — | — | EP | disclosed |
| US-7592346-B2 | e.g. 3-(3-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}phenyl)-1,3-oxazolidin-2-one; serotonin receptor antagonist and inverse agonists, agonists or partial agonists, serotonin reuptake inhibitor; antidepressant, anxiolytic agent | GLAXO GROUP LIMITED (GB) | 2009-09-22 | — | — | US | disclosed |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED | 2009-03-19 | — | — | US | disclosed |
| CN-100441571-C | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LTD (GB) | 2008-12-10 | — | — | CN | disclosed |
| US-7459456-B2 | Quinoline and quinazoline derivatives having affinity for 5HT1-type receptors | GLAXO GROUP LIMITED (GB) | 2008-12-02 | — | — | US | disclosed |
| US-20080280919-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED | 2008-11-13 | — | — | US | disclosed |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | GLAXO GROUP LIMITED (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1646613-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| US-6939871-B2 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-09-06 | — | — | US | disclosed |
| EP-1562917-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2005-08-17 | — | — | EP | disclosed |
| WO-2005014552-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004046124-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | GLAXO GROUP LIMITED (GB) | 2004-06-03 | — | — | WO | disclosed |
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | SMITHKLINE BEECHAM P.L.C (GB) | 2004-04-01 | — | — | US | disclosed |
| CN-1478092-A | Benzoxazinone derivatives, their preparation and use | ʷ | 2004-02-25 | — | — | CN | disclosed |
| EP-1330460-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM PLC (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002034754-A2 | BENZOXAZINONE DERIVATIVES, THEIR PREPARATION AND USE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063704-A1 | Benzoxazinone derivatives, their preparation and use | CYP2B6, CBR1, CYP2A6 | KMT2A 2934/4885OPRK1 75/4885CTSB 2893/4885 |
| US-20100204273-A1 | Quinoline and Quinazoline Derivatives Having Affinity for 5HT1-Type Receptors | OPRK1, OPRL1, OPRD1 | KMT2A 2415/4885OPRK1 1/4885CTSB 1918/4885 |
| US-20090312546-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | KMT2A 1738/4885OPRK1 24/4885CTSB 3626/4885 |
| US-20080280919-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES HAVING AFFINITY FOR 5HT1-TYPE RECEPTORS | HTR1A, HTR1D, HTR1F | KMT2A 1191/4885OPRK1 33/4885CTSB 3529/4885 |
| US-20090076274-A1 | BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS | XDH, CYP4X1, PDHX | KMT2A 1832/4885OPRK1 430/4885CTSB 2894/4885 |
| US-20060229312-A1 | Quinoline and quinazoline derivatives having affinity for 5ht1-type receptors | HTR1A, HTR1D, HTR1F | KMT2A 1284/4885OPRK1 39/4885CTSB 3916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.